CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
ongoing trials trial from www.clinicaltrials.gov

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) - Phase 1|Phase 2 - Not yet recruiting

  • Year: 2021
  • Date: February 1, 2021
  • Author: Yale University
Source

https://ClinicalTrials.gov/show/NCT04684641

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Cystic Fibrosis - 18 Years and older   (Adult, Older Adult)

Interventions

Drug: Standard Dose YPT-01|Drug: High Dose YPT-01|Other: Placebo

Outcome measures

Reduction in sputum bacterial culture|Change in lung function|Change in the rate of pulmonary exacerbations|Change in the rate of hospitalization|Change in the rate of acute antibiotic use|Patient's Quality of Life

Related topics

Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis

Antibiotic treatment of early pseudomonas aeruginosa

Antibiotics for pulmonary exacerbations

Inhaled antibiotics in cystic fibrosis

MRSA eradication in CF

Prophylactic use of oral antistaphylococcal antibiotic

Scheduled antibiotics every 3-4 months / symptom-based treatment

Keywords: YPT-01; Phage therapy; Anti-bacterial agents; pharmacological_intervention; Bacterial Infections; Infection; Inhalation OR nebulised; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections;